Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
Subscribe To Our Newsletter & Stay Updated
